BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Radiometal Conjugate



Radiometal conjugate of a BBN analogue that hashigh affinity for GRP receptors.

RMC=Radiometal chelate, where M=^{99m}Tc, $^{186/188}$Re, ^{105}Rh and X=chelating atoms.

SG=Spacer group or linker that covalently attaches the chelate to the N-terminal end of the BBN binding region (BBN_{BR})

Figure 1



ORTEP Drawing of {Rh[16]aneS$_4$-oICl$_2$}$^+$

Figure 2



Figure 3



Figure 4

Iodinated Bombesin Analogues

mIP-Lys^3-BOMBESIN



IC_{50}=2.13

BBN-18



IC_{50}=5.80

BBN-16i



IC_{50}=18826

BBN-9



IC_{50}=0.14

BBN-15i



IC_{50}=>40,000

Figure 5

Tethered Bombesin Analogues



Figure 6

[16]aneS$_4$ Bombesin Analogues



Figure 7


IC50 ANALYSIS
Non-Radioactive Displacing Ligand
%I-125-BBN Total Uptake
100
90
80
70
60
50
40
30
20
10
0
IC50
1e-011
1e-010
1e-009
1e-008
1e-007
1e-006
1e-005
Molar Concentration of Displacing Ligand

Figure 8

Rhodium-[16]aneS$_4$ Bombesin Analogues



Figure 9

A.



B.



HPLC Chromatogram of Rhodium-BBN-37
Top: $^{105}RhCl_2$-BBN-37
Bottom: $RhCl_2$-BBN-37

Figure 10


125I-Tyr4-Bombesin Internalization
Efflux in 125I-Tyr4-BBN Free Buffer
SCALED % I-125-BBN BOUND
110
100
90
80
70
60
50
40
30
20
10
0
-10
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
260
Time (Minutes)
Total Bound (Surface & Internalized)
Internalized
t=0 Represents 40min Equilibrium Binding at
Maximum Incorporation in 3T3 Cells

Figure 11


I-125 Bombesin Internalization
Efflux in I-125 Free Buffer
Scaled % I-125 Bound
110
100
90
80
70
60
50
40
30
20
10
0
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 210 220 230 240 250 260
Time (Minutes)
125I-Tyr4-Bombesin Internalized
125I-pIP-Lys3-Bombesin Internalized
t=0 Represents 40 min Equilibrium Binding
Maximum Value in Swiss 3T3 Cells

Figure 12



Figure 13

^{105}Rhodium Bombesin Analogues



Figure 14



Figure 15


Efflux of ^{105}Rh-BBN-22 vs. ^{105}Rh-BBN-37 in Swiss 3T3 Cells
(Non-Normalized Data)
Total % of ^{105}Rh Associated with Cell Compartments
Time (Hours)
^{105}Rh-BBN-22 Total Bound
^{105}Rh-BBN-22 Internalized
^{105}Rh-BBN-22 Surface Bound
^{105}Rh-BBN-37 Total Bound
^{105}Rh-BBN-37 Internalized
^{105}Rh-BBN-37 Surface Bound
0
2
4
6
8
10
12
14
16
18
20
22
0
1
2
3

Figure 16

Pancreatic CA Cell Binding

A.



B.



Figure 17

Prostate CA Cell Binding

A.



B.



Figure 18

[16]aneS_4 Bombesin Analogues

BBN-96



IC_{50} (nM)

Swiss 3T3	18.4 ± 4.5
PC - 3	8.8 ± 1.8
CF PAC - 1	39.5 ± 10.7

BBN-99



IC_{50} (nM)

Swiss 3T3	6.0 ± 0.5
PC - 3	3.3 ± 1.9
CF PAC - 1	4.8 ± 0.8

BBN-98



IC_{50}(nM)

Swiss 3T3	3.3 ± 0.2
PC - 3	4.3 ± 2.2
CF PAC - 1	6.1 ± 3.3

BBN-97



IC_{50}(nM)

Swiss 3T3	38.0 ± 11.7
PC - 3	6.9 ± 2.8
CF PAC - 1	14.2 ± 6.8

BBN-101



IC_{50}(nM)

Swiss 3T3	1.2 ± 0.7
PC - 3	2.1 ± 0.5
CF PAC - 1	2.4 ± 0.9

FIGURE 19

Rhodium-[16]aneS_4 Bombesin Analogues

BBN-99



	IC_{50} (nM)
Swiss 3T3	8.24 ± 0.67
PC - 3	4.97 ± 0.60
CF PAC - 1	4.64 ± 0.81

BBN-98



IC_{50}(nM)
2.84 ± 0.76
1.21 ± 0.19
1.32 ± 0.12

BBN-97



IC_{50}(nM)
9.30 ± 1.55
5.29 ± 092
3.70 ± 1.89

BBN-101



IC_{50}(nM)
5.42 ± 2.11
2.32 ± 1.52
0.73 ± 0.83

FIGURE 20



RP414-3C-BBN(7-14)



RP414-5C-BBN(7-14)



RP414-8C-BBN(7-14)

FIGURE 21

^{99m}Tc-BBN-122



14.319

HPLC Gradient Elution Program

Flow 1.5 ml/min
Solvent A = H_2O with 0.1% TFA
Solvent B = CH_3CN with 0.1% TFA

Time(min)	%A/%B
0	95/5
25	30/70
30	95/5



Figure 22

^{99m}Tc-BBN-122 Uptake in Human Prostate Cancer Cells



Figure 23

^{99m}Tc-BBN-122 Internalization in Human Pancreatic Cancer Cells



Figure 24

^{99m}Tc-BBN-122 Retention in Human Prostate Cancer Cells



Figure 25

^{99m}Tc-BBN-122 Retention in Human Pancreatic Cancer Cells



Figure 26

DOTA-BBN[7-14]NH_2 analogues.



DOTA-0-BBN(7-14)NH_2 DOTA-βAla-BBN(7-14)NH_2 DOTA-5Ava-BBN(7-14)NH_2 DOTA-8Aoc-BBN(7-14)NH_2 DOTA-11Aun-BBN(7-14)NH_2

FIGURE 27

HPLC chromatograms of (a) DOTA-BBN[7-14]NH_2 (λ = 280 nm) (b) In-DOTA-BBN[7-14]NH_2 (λ =280 nm) and (c) ^{111}In-DOTA-BBN[7-14]NH_2 (radiometric).



FIGURE 28

Competitive binding assay of In-DOTA-8-Aoc-BBN[7-14]NH_2 vs. ^{125}I-Tyr^4-BBN in PC-3 cells.



FIGURE 29

Internalization of ^{111}In-DOTA-8-Aoc-BBN[7-14]NH_2 in PC-3 cells.



FIGURE 30

Efflux of ^{111}In-DOTA-8-Aoc-BBN[7-14]NH_2 in PC-3 cells.



FIGURE 31



Figure 32